Company Dossier · Consumer Staples
Colgate-Palmolive
- S&P 500
- Russell 1000
What Colgate-Palmolive is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $21.1 billion, up 5.3% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $3.86 billion, up 15% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 30, 2026: $0.60 billion, up 9.1% from a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to December 31, 2025: $1.21 billion.SEC EDGAR filings (10-K)
- Long-term debt issued in the fiscal year to December 31, 2019: $8.06 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (July 31, 2026): sentiment 0.20 on a −1 to +1 scale (mixed), confidence 0.50 of 1.Palanor Discourse
- Guidance in the last 90 days: 2 outlook figures raised, 0 lowered, 2 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed February 23, 2026): 1 risk factor added, 1 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q3 2026: $31.0 million on the open market.SEC Form 4
- 2,031 institutional managers reported a position at June 30, 2026 (+65 on the quarter before).SEC Form 13F
- H-1B filings certified in Q1 2026: 1 (0 a year earlier).U.S. Department of Labor (OFLC)
Risk events (12 months): 2 — latest EPA enforcement case, Aug 31, 2026 →
Company Posture
How Company Posture is measured →What Colgate-Palmolive is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.
Steady · Mixed
Expanding ↔ Retrenching
Steady
- Capital spending78th pct
- Debt raised—
- Buybacks vs capex38th pct
- Hiring filings52nd pct
- Deals and private raises49th pct
- Patent publications30th pct
Confident ↔ Hedging
Mixed
- Call sentiment38th pct
- Call confidence18th pct
- Guidance changes87th pct
- Risk factors added30th pct
- Insider open-market trades40th pct
- + Guidance changes
- − Call confidence
- − Risk factors added
Pressure
Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).
- Fails-to-deliver33rd pct
- Stress filings48th pct
Credit
How these are built →Colgate-Palmolive's borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.
Debt on the balance sheet
$7.8B
- Due within a year $0.0B
- Longer term $7.8B
- Default point $3.9B (short + ½ long)
Finance leases included · Jun 30, 2026 filing
Bonds priced, last 12 months
None
U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.
| Priced | Amount | Coupon | Matures | Spread | Yield |
|---|---|---|---|---|---|
| Nov 3, 2025 | €600M | 3.250% | 2035 (10y) | +70bp | 3.369% |
| Apr 28, 2025 | $500M | 4.200% | 2030 (5y) | +38bp | 4.212% |
From the pricing term sheets Colgate-Palmolive filed with the SEC. Spread is to the benchmark Treasury (or Bund, Gilt) at pricing.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 18, 2026LobbyingLobbying report (ALPINE GROUP PARTNERS, LLC.)third_quarter 2026 · $0.1 million
- Oct 13, 2026Patent
- Oct 13, 2026PatentPatent granted: Personal Care CompositionsUS 12758486
- Oct 13, 2026Patent
- Oct 1, 2026LobbyingLobbying report (TAFT STETTINIUS & HOLLISTER LLP DBA TAFT ADVISORS LLC FKA (TAFT, STETTINIUS & HOLLISTER, LLP))third_quarter 2026 · $0.0 million
- Sep 15, 2026PatentPatent granted: Oral Care CompositionsUS 12734118
- Sep 15, 2026PatentPatent granted: DispenserUS 12735242
- Aug 31, 2026Risk event
- Jul 19, 2026LobbyingLobbying report (ALPINE GROUP PARTNERS, LLC.)second_quarter 2026 · $0.1 million
- Jul 1, 2026LobbyingLobbying report (TAFT STETTINIUS & HOLLISTER LLP DBA TAFT ADVISORS LLC FKA (TAFT, STETTINIUS & HO)second_quarter 2026 · $0.0 million
- May 13, 20268-KShareholder vote resultsItem 5.07
- May 1, 20268-KExit or restructuring costsItem 2.05
- Apr 20, 2026LobbyingLobbying report (ALPINE GROUP PARTNERS, LLC.)first_quarter 2026 · $0.1 million
- Apr 9, 20268-KDirector or officer changeItem 5.02
- Apr 1, 2026LobbyingLobbying report (TAFT STETTINIUS & HOLLISTER LLP DBA TAFT ADVISORS LLC FKA (TAFT, STETTINIUS & HO)first_quarter 2026 · $0.0 million
- Mar 12, 20268-KDirector or officer changeItem 5.02
- Feb 23, 202610-KAnnual report (10-K)1 risk factors added, 1 removed
- Jan 19, 2026LobbyingLobbying report (ALPINE GROUP PARTNERS, LLC.)fourth_quarter 2025 · $0.1 million
- Jan 2, 2026LobbyingLobbying report (TAFT STETTINIUS & HOLLISTER LLP DBA TAFT ADVISORS LLC FKA (TAFT, STETTINIUS & HO)fourth_quarter 2025 · $0.0 million
- Dec 10, 2025Risk event
- Oct 31, 20258-KExit or restructuring costsItem 2.05
- Aug 1, 20258-KExit or restructuring costsItem 2.05
- May 29, 20258-KDirector or officer changeItem 5.02
- May 14, 20258-KShareholder vote resultsItem 5.07
- Feb 13, 202510-KAnnual report (10-K)1 risk factors added, 1 removed
- Feb 15, 202410-KAnnual report (10-K)0 risk factors added, 0 removed
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Kimberly-Clark KMB | $16.6B | $1.8B | Jun 30, 2026 |
| Clorox CLX | $6.8B | $0.4B | Mar 31, 2026 |
| Church & Dwight CHD | $6.2B | — | Jun 30, 2026 |
| Procter & Gamble PG | $87.0B | $15.2B | Jun 30, 2026 |
| Keurig Dr Pepper KDP | $20.1B | $2.0B | Jun 30, 2026 |
| BJ's Wholesale Club BJ | $22.8B | $0.4B | Aug 1, 2026 |
| Altria Group MO | $23.5B | $9.1B | Jun 30, 2026 |
| Casey's CASY | $18.7B | $0.7B | Jul 31, 2026 |